Knight Therapeutics Inc.

to NICE Therapeutics Inc. fourth quarter and year-end 2021 results conference call. Before turning the call over to Samira Zakia, President and CEO of NICE listeners, I'm reminded that portions of today's discussion may by their nature necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. The company considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, by caution that these assumptions regarding the future events, many of which are beyond the control of the company and its subsidiaries, may ultimately prove to be incorrect. The company disclaims any intention or obligation to update or reverse any forward-looking statements, whether a result of new information, future events, except as required by law. We would also like to remind you, questions during today's call will be taken from analysts only. Should there be any further questions, please contact Knight's Investor Relations Department via email to info at knighttx.com or via phone at 514-484-4483. would like to remind everyone that this call is being recorded today march 24th 2022 and would now like to turn the meeting over to your host for today's call samira sakia please go ahead ma'am thank you emma good morning and welcome to night therapeutics fourth quarter and your end conference call i'm joined in today's call with amal curry our chief business officer

Arvind Uchina, our Chief Financial Officer, who recently moved to Uruguay and is participating for Montevideo. Jeff Martins, our Global VP of Commercial, who is on the last leg of a three-country tour and is joining the call from Bogota, Colombia. I'm excited to report that 2021 was a record-setting year in Knight's history, despite the ongoing challenges posed by the pandemic. During the year, we made significant strides with completing the integration of the group of BioToscana acquisition, all the while strengthening the team and processes and driving strong performance. More specifically, we strengthened Knight's management team with the addition of four new executives last year, and I'm happy to announce that Leopoldo Bozzano has recently joined Knight as VP of Manufacturing and Operations. Leopoldo has nearly 30 years of experience in operations management, including over 25 years in the pharmaceutical industry. He joins Knight from Giveran Argentina, where he had been working since 2014, most recently as head of operations at LATAM. At GIVEDAN, he was responsible for production, quality control, quality assurance, supply chain, engineering, maintenance across seven sites located in Argentina, Chile, Brazil, Colombia, and Mexico. Prior to GIVEDAN, Leopoldo worked at HLB Pharma, where he was industrial operations director. In addition, he worked as general manager and VP at UVViz Metrolab in Argentina. Prior to these roles, Leopoldo was at Prismar Squibb for many years in Argentina, as well as in Panama, where he held several roles, including planning, supply chain procurement, technical operations, plant management, and GM for supply to Middle and Far East and Latin American markets. Leopoldo is based in Buenos Aires. In addition to the management team changes, we made integration advances with the implementation of several global systems, including CRM, pharmacovigilance systems, HR systems, and we have implemented our ERP system in 14 entities in six countries. We expect to complete the ERP implementation in all entities except the Argentinian affiliates by the end of 22. On the existing portfolio, Our regulatory team advanced our product pipeline with the approval of Halivant and Lendvima in Colombia, as well as Rembray, Knights Desatinib branded generic, also for Colombia. We also obtained approval for Neuralynx in metastatic breast cancer, which is the second approved indication for Neuralynx in Canada. On the commercial side, our team continued to generate strong growth on our key brands, delivering record revenues in 2021. Turning now to the NCIB, during the year we purchased approximately 12.3 million shares for aggregate cash consideration of $64.4 million at an average price of $5.23 per share. Subsequent to the year, Knight has purchased an additional 934,000 common shares for aggregate cash consideration of $5 million or $5.35 per share. I will now turn the call over to Jeff to provide more details on our product results.

Thank you, Samara. Building on our hard work of 2020, our efforts in 2021 remain focused on executional excellence of our new product launches while delivering competitive growth for our mature promoted portfolio. Overall, the year ended December 31st, 2021. Our revenues on a constant currency basis increased by $48.3 million or 26 versus the prior year. The growth in revenues is driven by $21 million resulting from the addition of Exelon, $15 million in net revenues related to the growth of our recently launched products, and the balance due to incremental demand estimated to be between $13.5 to $16.3 million, primarily driven by our infectious disease products that treat invasive fungal infections associated with COVID-19. As the last COVID wave dissipates, our team in the field is excited to get back to normal post-COVID activities. And with that, I'm happy to announce that we launched LaVima and Rembrae in Colombia in February and launched Halod and also in Colombia in March of this year. I will now turn the call over to Arvind to go over our financial results.